Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation

a technology of dehydroepiandrosterone and parthenolide, which is applied in the field of reducing inflammation, can solve the problems of unfavorable inflammation, unfavorable consequences, and inflammation arising from a disease or an inappropriate immunological response, and achieve the effect of reducing inflammation and reducing inflammation

Inactive Publication Date: 2006-06-08
INFLABLOC PHARMA
View PDF13 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While inflammation can primarily be a favorable defense mechanism, it can also have unfavorable consequences when it is an inappropriate immunological response incited by a non-harmful substance.
Additionally, diseases such as human inflammatory disorders, infectious disorders, and autoimmune disorders can also result in unfavorable inflammation.
Additionally, inflammation arising from a disease or an inappropriate immunological response can have other physiological effects that may not be desirable including fever, malaise, nausea, enlarged lymph nodes, increased erythrocyte sedimentation, and leucocytosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation
  • Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation
  • Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation

Examples

Experimental program
Comparison scheme
Effect test

example

Synergistic Effect of DHEA and Parthenolide on TNF-α Release

[0108] THP-1 macrophages were stimulated with lipopolysaccharide and treated with either DHEA, parthenolide (PTH), or a combination of the two compounds. The amount of TNF-α released was measured. The fold change in TNF-α over basal levels as a result of each treatment is shown in FIG. 1. Treatment with a combination of 5 μM parthenolide and 10 μM DHEA produced a greater suppression of TNF-α than treatment with either 5 μM parthenolide or 10 μM DHEA alone. This suppression was also greater than the sum of the suppressive effects produced from treatment with 5 μM parthenolide and 10 μM DHEA.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
compositionaaaaaaaaaa
temperatureaaaaaaaaaa
swellingaaaaaaaaaa
Login to view more

Abstract

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation.

Description

PRIORITY DATA [0001] The present application is a continuation-in-part of U.S. patent application Ser. No. 11 / 145,024, filed Jun. 3, 2005, which claims the benefit of U.S. Provisional Application No. 60 / 584,350 filed Jun. 30, 2004, both of which are incorporated herein by reference in their entireties.FIELD OF THE INVENTION [0002] The present invention is drawn to methods of reducing inflammation. More particularly, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation. BACKGROUND OF THE INVENTION [0003] Inflammation within a human subject is a common physiological response by the immune system to an injury or irritation, where the irritation can be by infectious, allergic, and / or chemical irritants. Some of the clinically observable symptoms of inflammation include increased redness, temperature, swelling, and pain, as well as the loss of function within the inflamed area. These s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/57A61K31/365
CPCA61K31/202A61K31/415A61K31/5685A61K2300/00
Inventor PATEL, DINESHVOLLMER, DAVIDDAUGHERTY, CLAIREGEBHARD, JOHN
Owner INFLABLOC PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap